A Breakthrough for Those Who’ve Had to Stop Their Medication

If you’ve ever had to pause your infliximab treatment due to surgery, infection, or other health concerns, you know the anxiety that comes with wondering if the medication will work as well when you restart. New research presented at ECCO 2026 brings encouraging news that could transform how we approach treatment interruptions in IBD care. For the first time, we have solid evidence that switching to subcutaneous infliximab after a treatment break can help people with Crohn’s disease and ulcerative colitis regain and maintain remission effectively.

This development is particularly significant because treatment interruptions are more common than many realize, affecting up to 30% of people on biologic therapies at some point in their IBD journey. The fear of losing response to a medication that once provided relief has kept many patients and doctors hesitant about necessary treatment breaks.

What the New Research Shows

According to the source, a new post-hoc analysis from the LIBERTY studies presented at the European Crohn’s and Colitis Organisation (ECCO) 2026 conference demonstrated promising results for subcutaneous infliximab (Remsima™ SC). The research specifically examined what happens when patients initiate subcutaneous infliximab after experiencing a treatment interruption following their initial intravenous infliximab induction therapy.

The study focused on patients with both Crohn’s disease and ulcerative colitis who had previously been on intravenous infliximab but needed to stop their treatment for various reasons. Rather than returning to IV infusions, these patients were transitioned to the subcutaneous formulation of the same medication. The results showed that this approach effectively helped patients recapture their previous response and maintain clinical remission.

The LIBERTY studies represent one of the most comprehensive examinations of subcutaneous infliximab to date, and this particular analysis addresses a critical gap in our understanding of how to manage treatment interruptions in IBD care. The data suggests that the subcutaneous route may offer advantages not just in convenience, but also in maintaining therapeutic effectiveness after treatment breaks.

What This Means for Your IBD Journey

This research represents a significant shift in how we might approach treatment interruptions in IBD care, and the implications for patients are profound. For years, the prospect of stopping infliximab—even temporarily—has been fraught with uncertainty. Many people with IBD have delayed necessary surgeries or endured infections longer than advisable because they feared losing their hard-won remission.

The subcutaneous option changes this dynamic entirely. First, it addresses one of the most practical concerns about restarting infliximab: the time and inconvenience of returning to infusion centers. After experiencing the freedom that comes with stable IBD, the thought of returning to lengthy hospital visits every eight weeks can feel overwhelming. Subcutaneous injections, which can be self-administered at home, eliminate this barrier and give patients more control over their treatment schedule.

But the benefits extend far beyond convenience. The research suggests that the subcutaneous formulation may actually be better at recapturing remission after interruptions than returning to IV therapy. This could be due to several factors, including more consistent drug levels with subcutaneous dosing and potentially reduced immunogenicity—the development of antibodies that can make the medication less effective over time.

For patients who have experienced multiple treatment failures, this news is particularly encouraging. The fear of “burning through” effective treatments has led many to stick with medications that provide only partial relief, worried that switching might leave them with fewer options. The ability to successfully restart infliximab in a new formulation after an interruption essentially extends the useful life of this important medication.

The psychological impact cannot be understated either. Knowing that a treatment interruption doesn’t necessarily mean the end of your relationship with a successful medication can reduce the anxiety that often surrounds necessary medical procedures or the management of concurrent health issues. This peace of mind can improve overall quality of life and may even lead to better long-term outcomes as patients feel more confident about taking necessary health risks.

From a practical standpoint, this development also opens up new possibilities for treatment planning. Gastroenterologists may now feel more comfortable recommending treatment breaks when clinically appropriate, knowing they have a viable path back to effective therapy. This could be particularly relevant for patients planning pregnancies, needing surgery, or dealing with recurrent infections.

The timing of this research is also significant as healthcare systems worldwide continue to grapple with capacity issues. Subcutaneous treatments reduce the burden on infusion centers, potentially making biologic therapies more accessible to more patients. For rural patients or those with transportation challenges, the ability to self-administer at home could be life-changing.

Expert Perspectives on Treatment Interruption Management

Gastroenterologists have long recognized that treatment interruptions are sometimes unavoidable in IBD care, but until now, the best practices for restarting therapy have been based more on clinical experience than robust evidence. IBD specialists typically recommend that patients discuss any planned interruptions well in advance, as the timing and duration can significantly impact outcomes.

The medical community has increasingly recognized that the “one-size-fits-all” approach to biologic therapy may not serve all patients optimally. Some individuals may benefit from more frequent dosing, others from different delivery methods, and still others from strategic treatment holidays. This new data provides gastroenterologists with evidence-based options for personalizing care, particularly for patients who require treatment interruptions.

Experts emphasize that any treatment interruption should be carefully planned and monitored. The decision to stop and restart infliximab, whether in IV or subcutaneous form, should always involve detailed discussions about risks, benefits, and monitoring strategies with your healthcare team.

Key Takeaways for IBD Patients

• Treatment interruptions don’t have to mean permanent loss of infliximab effectiveness – subcutaneous formulations may offer a viable restart option
• Discuss subcutaneous options with your gastroenterologist if you’re facing a necessary treatment break or struggling with IV infusion logistics
• Home-based subcutaneous therapy could provide more flexibility in managing your treatment schedule around work, family, and other health needs
• This development may reduce anxiety around necessary medical procedures that require temporary medication stops
• Consider this option if you’ve had previous infliximab interruptions and are concerned about restarting IV therapy

Looking Forward with Renewed Hope

This research represents more than just a new treatment option—it’s a paradigm shift that could fundamentally change how we approach IBD care continuity. For a community that has learned to live with the constant fear of treatment failure and limited options, having evidence that effective medications can be successfully restarted in new formulations is genuinely transformative.

As we await more detailed publication of these findings, the IBD community can feel cautiously optimistic about having more tools in the treatment toolkit. The ability to maintain therapeutic relationships with effective medications despite necessary interruptions could improve both clinical outcomes and quality of life for countless patients.

What questions does this research raise for your own IBD management? Have you experienced treatment interruptions, and how might subcutaneous options fit into your care plan? Share your thoughts and experiences with our community—your insights could help others navigate similar decisions.